Equities Analysts Issue Forecasts for CervoMed Q1 Earnings

CervoMed Inc. (NASDAQ:CRVO) – Equities researchers at Roth Capital boosted their Q1 2025 earnings per share (EPS) estimates for CervoMed in a research report issued to clients and investors on Tuesday, December 10th. Roth Capital analyst B. Pachaiyappan now forecasts that the company will post earnings per share of ($0.52) for the quarter, up from their previous forecast of ($0.53). Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.76) per share. Roth Capital also issued estimates for CervoMed’s Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.27) EPS and FY2025 earnings at ($1.57) EPS.

CervoMed (NASDAQ:CRVO) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.14). CervoMed had a negative return on equity of 44.11% and a negative net margin of 118.68%. The company had revenue of $1.94 million during the quarter, compared to analysts’ expectations of $1.75 million.

A number of other equities analysts also recently weighed in on the stock. Brookline Capital Management downgraded shares of CervoMed from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Chardan Capital reissued a “neutral” rating on shares of CervoMed in a research note on Wednesday. Morgan Stanley reiterated an “underweight” rating on shares of CervoMed in a research note on Wednesday. HC Wainwright assumed coverage on shares of CervoMed in a research note on Thursday, December 5th. They set a “buy” rating and a $42.00 price target on the stock. Finally, D. Boral Capital reaffirmed a “hold” rating on shares of CervoMed in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, CervoMed presently has an average rating of “Moderate Buy” and a consensus price target of $42.00.

CervoMed Trading Down 1.0 %

CRVO stock opened at $1.93 on Friday. The company has a 50 day moving average of $11.51 and a two-hundred day moving average of $14.76. CervoMed has a 12-month low of $1.83 and a 12-month high of $26.38.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Barclays PLC grew its position in CervoMed by 323.6% in the third quarter. Barclays PLC now owns 7,748 shares of the company’s stock valued at $113,000 after acquiring an additional 5,919 shares during the period. Geode Capital Management LLC raised its position in CervoMed by 13.9% in the 3rd quarter. Geode Capital Management LLC now owns 114,934 shares of the company’s stock valued at $1,678,000 after purchasing an additional 14,042 shares during the last quarter. State Street Corp boosted its stake in CervoMed by 28.1% in the third quarter. State Street Corp now owns 104,456 shares of the company’s stock worth $1,525,000 after purchasing an additional 22,903 shares in the last quarter. FMR LLC bought a new stake in CervoMed during the 3rd quarter worth about $56,000. Finally, Citizens Financial Group Inc. RI grew its stake in shares of CervoMed by 13.2% during the third quarter. Citizens Financial Group Inc. RI now owns 30,509 shares of the company’s stock valued at $445,000 after purchasing an additional 3,553 shares during the last quarter. Institutional investors and hedge funds own 25.15% of the company’s stock.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.